nach oben

Journal of Neural Transmission

Erschienen in:

01.04.2009 | Dementias - Original Article

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis

verfasst von: Bai-song Wang, Hao Wang, Zhao-hui Wei, Yan-yan Song, Lu Zhang, Hong-zhuan Chen

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to provide an updated meta-analysis of the efficacy and safety of huperzine A (HupA) in Alzheimer’s disease (AD). We searched for randomized trials comparing HupA with placebo in the treatment of AD. The primary outcome measures were mini-mental state examination (MMSE) and activities of daily living scale (ADL). Data were extracted from four randomized clinical trials and analyzed using standard meta-analysis and meta-regression methods. Oral administration of HupA for 8–24 weeks (300–500 μg daily) led to significant improvements in MMSE and ADL. The results of meta-regression showed that the estimated effect size of MMSE and ADL was increased over the treatment time. Most adverse events were cholinergic in nature and no serious adverse events occurred. Huperzine A is a well-tolerated drug that could significantly improve cognitive performance and ADL in patients with AD.

Bai DL, Tang XC, He XC (2000) Huperzine A, a potential therapeutic agent for treatment of Alzheimer’s disease. Curr Med Chem 7:355–374PubMed

Chen MJ, Gao ZX, Deng HY, Liu FG (2000) A multi-center, double-blind clinical trial of huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Chin J New Drugs Clin Rem 19:10–12

Dong HT, Jin YG, Bai Y (2002) 11 cases of Alzheimer’s disease treated by acupuncture. Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai 16:26–28

Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45:769–773PubMedCrossRef

Folstein M, Folstein S, McHugh P (1975) The mini-mental state examination. J Psychiatr Res 12:189–198PubMedCrossRef

Giacobini E (2004) Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 50:433–440PubMedCrossRef

Isaac MG, Quinn R, Tabet N (2008) Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev (3). Art. No.: CD002854. doi: 10.1002/14651858.CD002854

Kelley BJ, Knopman DS (2008) Alternative medicine and Alzheimer disease. Neurologist 14:299–306PubMedCrossRef

Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186PubMed

Li J, Wu HM, Zhou RL, Liu GJ, Dong BR (2008) Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev (2). Art. No.: CD005592. doi:10.1002/14651858.CD005592

Little JT, Walsh S, Aisen PS (2008) An update on huperzine A as a treatment for Alzheimer’s disease. Expert Opin Investig Drugs 17:209–215PubMedCrossRef

Liu FG, Fang YS, Gao ZX, Zhou JD, Su ML (1995) Double-blind control treatment of huperzine-A and placebo in 28 patients with Alzheimer disease. Chin J Pharmacoepidemiol 4:196–197

Ma X, Tan C, Zhu D, Gang DR, Xiao P (2007) Huperzine A from Huperzia species—an ethnopharmacolgical review. J Ethnopharmacol 113:15–34PubMedCrossRef

Mazurek A (2000) An open-label trial of huperzine A in the treatment of Alzheimer’s disease. Altern Ther Health Med 5:97–98

Normand SLT (1999) Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 18:321–359PubMedCrossRef

Rogers SL, Doody RS, Hohs RC, Friedhoff LT, Donepezil Study Group (1998a) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind placebo-controlled study. Arch Intern Med 158:1021–1031PubMedCrossRef

Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50:136–145PubMed

Schneider LS (2001) Assessing outcomes in Alzheimer disease. Alzheimer Dis Assoc Disord 15:S8–S18PubMedCrossRef

Tang XC, De Sarno P, Sugaya K, Giacobini E (1989) Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 24:276–285PubMedCrossRef

Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573PubMedCrossRef

Van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21:589–624PubMedCrossRef

Ved HS, Koenig ML, Dave JR, Doctor BP (1997) Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 8:963–968PubMedCrossRef

Wang R, Yan H, Tang XC (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27:1–26PubMedCrossRef

Whitehead A (2002) Meta-analysis of controlled clinical trial. Wiley, ChichesterCrossRef

Wong DM, Greenblatt HM, Dvir H, Carlier PR, Han YF, Pang YP, Silman I, Sussman JL (2003) Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. J Am Chem Soc 125:363–373PubMedCrossRef

Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, Zhang ML, Tong ZH, Fang YS, Chai XS, Li SL (1995) Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacol Sin 16:391–395

Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B (1999) Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Acta Pharmacol Sin 20:486–490

Yan H, Tang XC (2006) Review on clinical application of huperzine A in China. Chin J New Drugs Clin Rem 25:682–687

Yang JS, Jiang ZH (1996) The clinical report of the effect of huperzine A in treatment of Alzheimer’s disease. Heibei Jing Shen Wei Sheng 9:84–85

Yang CY, Lu ZP, Zheng CG (2003) Efficacy and reliability of huperzine A in mild and moderate Alzheimer’s disease. Chin J Clin Rehabil 7:4258–4259

Zhang HY, Tang XC (2006) Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27:619–625PubMedCrossRef

Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ, Shan GL (2002) Clinical efficacy and safety of huperzine A in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 82:941–944PubMed

Zhang ML, Yuan GZ, Yao JJ, Bi P, Ni SQ (2006) Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer’s disease. Chin J New Drugs Clin Rem 25:693–695

Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, Tang XC (2008) Potential therapeutic targets of huperzine A for Alzheimer’s disease and vascular dementia. Chem Biol Interact 175:396–402PubMedCrossRef

Zhou BR, Xu ZQ, Kuang YF, Deng YH (2004) Curative effect of aspirin for postponing the development of Alzheimer’s disease. Chin J Clin Rehabil 8:3020–3021

Titel: Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis
verfasst von: Bai-song Wang
Hao Wang
Zhao-hui Wei
Yan-yan Song
Lu Zhang
Hong-zhuan Chen
Publikationsdatum: 01.04.2009
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 4/2009
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0189-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability

Experience with long-term treatment with albumin-supplemented botulinum toxin type A

Expression of GluR6 kainate receptor subunit in granular layer of weaver mouse cerebellum

Neuregulin 1 and age of onset in the major psychoses

Accumbal noradrenaline that contributes to the alpha-adrenoceptor-mediated release of dopamine from reserpine-sensitive storage vesicles in the nucleus accumbens is derived from alpha-methyl-para-tyrosine-sensitive pools

Auricular vagus somatosensory evoked potentials in vascular dementia